Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig
- PMID: 2922891
- DOI: 10.1007/BF00261051
Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig
Abstract
The only form of effective immunotherapy for human cancer is the intravesical administration of BCG in the treatment of superficial bladder tumors. In this study BCG was administered intravesically (once a week for six consecutive weeks) in guinea pigs to investigate the immune response. Both specific immune responses against BCG itself and nonspecific immune responses such as leukocyte subset distribution, mitogenic (ConA, PHA, LPS) lymphocyte stimulation and spontaneous cytotoxic (NK and LAK cell) activity were determined in the regional draining (iliac) lymph node and in the spleen. The PPD skin test became positive after the fourth intravesical instillation of BCG when 1 X 10(5) culturable particles or higher dosages of BCG were administered. A low dose of 1 X 10(3) c.p. of BCG induced a positive PPD skin reaction in 2 of 4 animals after six BCG instillations. After six BCG instillation BCG immune lymphocytes were present both in the iliac lymph nodes and in the spleen. No differences in mitogenic responses to ConA, PHA and LPS were observed in iliac lymph nodes or the spleen between placebo or BCG treated animals. In the regional iliac lymph nodes a significantly increased number of leukocytes was present. These lymph node cells showed a significant increase in the expression of MHC class II (Ia) immune response antigen on their surface. In the spleen no differences were observed after BCG administration regarding the number of cells present and in terms of the Ia antigen expression of the leukocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.Urol Res. 1994;22(4):239-45. doi: 10.1007/BF00541900. Urol Res. 1994. PMID: 7871637
-
Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.Cancer Immunol Immunother. 1989;28(4):287-95. doi: 10.1007/BF00205239. Cancer Immunol Immunother. 1989. PMID: 2784716 Free PMC article.
-
Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.Prog Clin Biol Res. 1992;378:81-93. Prog Clin Biol Res. 1992. PMID: 1301589
-
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.Urol Int. 1990;45(3):129-36. doi: 10.1159/000281694. Urol Int. 1990. PMID: 2190404 Review.
-
[Mechanism of action of intravesical BCG. Biological bases and clinical applicability.].Arch Esp Urol. 2018 May;71(4):358-375. Arch Esp Urol. 2018. PMID: 29745925 Review. Spanish.
Cited by
-
Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.Cancer Immunol Immunother. 1990;31(3):182-6. doi: 10.1007/BF01744734. Cancer Immunol Immunother. 1990. PMID: 2337907 Free PMC article.
-
Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.Urol Res. 1994;22(4):239-45. doi: 10.1007/BF00541900. Urol Res. 1994. PMID: 7871637
-
Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.World J Urol. 1994;12(1):27-37. doi: 10.1007/BF00182048. World J Urol. 1994. PMID: 7516779
-
Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.Urol Res. 1997;25(2):117-20. doi: 10.1007/BF01037926. Urol Res. 1997. PMID: 9144878 Clinical Trial.
-
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.Cancer Immunol Immunother. 1991;33(6):411-6. doi: 10.1007/BF01741603. Cancer Immunol Immunother. 1991. PMID: 1878894 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Research Materials